Retatrutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 12 registered trials.

Why this status

  1. 30 May 2023: Trial started, NCT05882045
  2. 31 May 2023: Trial registered, NCT05882045
  3. 3 Jul 2023: Trial registered, NCT05929066
  4. 3 Jul 2023: Trial registered, NCT05929079
  5. 5 Jul 2023: Trial registered, NCT05931367
  6. 10 Jul 2023: Trial started, NCT05929066
  7. 11 Jul 2023: Trial started, NCT05929079
  8. 1 Aug 2023: Trial started, NCT05931367
  9. 28 Oct 2024: Trial registered, NCT06662383
  10. 1 Nov 2024: Trial started, NCT06662383
  11. 29 May 2025: Trial started, NCT07035093
  12. 24 Jun 2025: Trial registered, NCT07035093
  13. 17 Nov 2025: Trial started, NCT07232719
  14. 18 Nov 2025: Trial registered, NCT07232719
  15. 22 Jan 2026: Trial registered, NCT07357415
  16. 24 Jan 2026: Trial started, NCT07357415

The trials

NCT04881760: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

State
Completed
Phase
Phase 2
People
338 taking part
Started
20 May 2021
Primary completion
16 May 2022
Arms
1 milligram (mg) LY3437943, 4 mg LY3437943 (2 mg), 4 mg LY3437943, 8 mg LY3437943 (2 mg), 8 mg LY3437943 (4 mg), 12 mg LY3437943 (2 mg)
Results
Posted on the registry
  1. 11 May 2021: Trial registered
  2. 20 May 2021: Trial started
  3. 22 Nov 2022: Trial completed
  4. 13 Sep 2023: Trial results posted

NCT05548231: A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

State
Completed
Phase
Phase 1
People
32 taking part
Started
24 Oct 2022
Primary completion
27 Jul 2023
Arms
LY3437943
Results
None posted
  1. 21 Sep 2022: Trial registered
  2. 24 Oct 2022: Trial started
  3. 27 Jul 2023: Trial completed

NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

State
Completed
Phase
Phase 3
People
1,946 taking part
Started
30 May 2023
Primary completion
16 Apr 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2
Results
None posted
  1. 30 May 2023: Trial started
  2. 31 May 2023: Trial registered
  3. 14 May 2026: Trial completed

NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

State
Completed
Phase
Phase 3
People
2,335 taking part
Started
10 Jul 2023
Primary completion
6 Apr 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3, Retatrutide Extension Period
Results
None posted
  1. 3 Jul 2023: Trial registered
  2. 10 Jul 2023: Trial started
  3. 30 Apr 2026: Trial completed

NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

State
Completed
Phase
Phase 3
People
1,152 taking part
Started
11 Jul 2023
Primary completion
16 Jun 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3
Results
None posted
  1. 3 Jul 2023: Trial registered
  2. 11 Jul 2023: Trial started
  3. 16 Jun 2026: Trial completed

NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

State
Completed
Phase
Phase 3
People
445 taking part
Started
1 Aug 2023
Primary completion
14 Nov 2025
Arms
Retatrutide Dose 1, Retatrutide Dose 2
Results
None posted
  1. 5 Jul 2023: Trial registered
  2. 1 Aug 2023: Trial started
  3. 14 Nov 2025: Trial completed

NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

State
Completed
Phase
Phase 2
People
146 taking part
Started
20 Jul 2023
Primary completion
1 Oct 2025
Arms
Retatrutide
Results
Posted on the registry
  1. 7 Jul 2023: Trial registered
  2. 20 Jul 2023: Trial started
  3. 21 Oct 2025: Trial completed
  4. 9 Nov 2026: Trial results posted

NCT06313528: A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

State
Completed
Phase
Phase 1
People
85 taking part
Started
20 Mar 2024
Primary completion
26 Aug 2025
Arms
LY3437943
Results
None posted
  1. 15 Mar 2024: Trial registered
  2. 20 Mar 2024: Trial started
  3. 26 Aug 2025: Trial completed

NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

State
Under way
Phase
Phase 3
People
800 planned
Started
1 Nov 2024
Primary completion
Nov 2026
Arms
Retatrutide
Results
None posted
  1. 28 Oct 2024: Trial registered
  2. 1 Nov 2024: Trial started

NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

State
Under way
Phase
Phase 3
People
586 planned
Started
29 May 2025
Primary completion
Sep 2027
Arms
Retatrutide
Results
None posted
  1. 29 May 2025: Trial started
  2. 24 Jun 2025: Trial registered

NCT07232719: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

State
Under way
Phase
Phase 3
People
250 planned
Started
17 Nov 2025
Primary completion
Jun 2027
Arms
Retatrutide Dose 1, Retatrutide Dose 2
Results
None posted
  1. 17 Nov 2025: Trial started
  2. 18 Nov 2025: Trial registered

NCT07357415: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

State
Under way
Phase
Phase 3
People
600 planned
Started
24 Jan 2026
Primary completion
Oct 2028
Arms
Retatrutide Dose Escalation 1, Retatrutide Dose Escalation 2, Retatrutide Dose Escalation 3
Results
None posted
  1. 22 Jan 2026: Trial registered
  2. 24 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.